Symbols / ELDN $2.74 +1.86%
ELDN Chart
About
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company also has a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 218.19M |
| Enterprise Value | 71.54M | Income | -82.67M | Sales | — |
| Book/sh | 1.52 | Cash/sh | 1.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 31 | IPO | — |
| P/E | — | Forward P/E | -2.91 | PEG | — |
| P/S | — | P/B | 1.81 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 6.59 |
| Current Ratio | 6.74 | Debt/Eq | 0.79 | LT Debt/Eq | — |
| EPS (ttm) | -1.30 | EPS next Y | -0.94 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-19 | ROA | -44.22% |
| ROE | -95.49% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 79.63M |
| Shs Float | 54.44M | Short Float | 8.81% | Short Ratio | 9.75 |
| Short Interest | — | 52W High | 4.60 | 52W Low | 1.35 |
| Beta | 0.96 | Avg Volume | 850.34K | Volume | 1.19M |
| Target Price | $8.00 | Recom | Strong_buy | Prev Close | $2.69 |
| Price | $2.74 | Change | 1.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$2.74
Latest analyst target
3. DCF / Fair value
$-8.37
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.74
Low
$4.00
High
$12.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-18 | main | Guggenheim | Buy → Buy | $8 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-07-25 | init | Craig-Hallum | — → Buy | $12 |
| 2024-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-05-07 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-10-24 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-09-27 | init | Noble Capital Markets | — → Outperform | $10 |
| 2023-08-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $9 |
| 2023-05-26 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2022-06-01 | main | SVB Leerink | — → Outperform | $26 |
| 2021-11-24 | main | HC Wainwright & Co. | — → Buy | $25 |
| 2021-04-27 | main | SVB Leerink | — → Outperform | $33 |
| 2021-03-23 | init | Cantor Fitzgerald | — → Overweight | $25 |
| 2021-02-08 | init | SVB Leerink | — → Outperform | $34 |
- Experimental transplant drug lets 10 diabetes patients stop insulin - Stock Titan Mon, 16 Mar 2026 11
- Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tegopribart - GuruFocus Mon, 16 Mar 2026 22
- Leerink Partners reiterates Outperform on Eledon stock at $5 - Investing.com Mon, 16 Mar 2026 15
- With 51% ownership in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), institutional investors have a lot riding on the business - simplywall.st Sat, 18 Oct 2025 07
- Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is largely controlled by institutional shareholders who own 51% of the company - Yahoo Finance hu, 09 Oct 2025 07
- ELDN SEC Filings - Eledon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 04 Mar 2026 20
- Eledon Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview - TradingView Mon, 16 Mar 2026 11
- ELDN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI hu, 12 Mar 2026 17
- Why Is Eledon Pharmaceuticals Stock (ELDN) Down 50% Today? - TipRanks Fri, 07 Nov 2025 08
- Eledon Pharma wins FDA orphan status for lead asset (ELDN) - Seeking Alpha ue, 10 Mar 2026 12
- Eledon Pharmaceuticals (ELDN) Presents Promising Diabetes Trial Results - GuruFocus ue, 17 Mar 2026 01
- Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects - Yahoo Finance Sun, 09 Nov 2025 08
- Stem-cell islets plus immune drug: NewcelX, Eledon target Type 1 diabetes - Stock Titan Mon, 09 Mar 2026 11
- Eledon Pharmaceuticals stock rises after positive islet transplant data - Investing.com ue, 18 Nov 2025 08
- Eledon execs join fireside chat at Leerink 2026 health conference - Stock Titan Wed, 04 Mar 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3430 | — | — | HILLSON JAN M.D. PH.D. | Director | — | 2026-01-09 00:00:00 | D | nan |
| 1 | 3430 | — | — | KIRK ALLAN | Director | — | 2026-01-09 00:00:00 | D | nan |
| 2 | 3430 | — | — | ROBINSON JAMES A JR. | Director | — | 2026-01-09 00:00:00 | D | nan |
| 3 | 3430 | — | — | MCBRIDE JOHN S | Director | — | 2026-01-09 00:00:00 | D | nan |
| 4 | 3430 | — | — | LEE JUNE YONG | Director | — | 2026-01-09 00:00:00 | D | nan |
| 5 | 8575 | — | — | KATKIN KEITH A | Director | — | 2026-01-09 00:00:00 | D | nan |
| 6 | 1927937 | — | Purchase at price 2.40 per share. | BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | — | 2024-05-09 00:00:00 | I | 4627049.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 6.49M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.06 |
| NormalizedEBITDA | -101.12M | 33.59M | 9.24M | -36.67M |
| TotalUnusualItems | 30.90M | -76.21M | -48.65M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 30.90M | -76.21M | -48.65M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -36.18M | -116.54M | -87.97M | -34.51M |
| ReconciledDepreciation | 359.00K | 374.00K | 373.00K | 195.00K |
| EBITDA | -70.22M | -42.63M | -39.41M | -36.67M |
| EBIT | -70.58M | -43.00M | -39.78M | -36.87M |
| NetInterestIncome | 0.00 | |||
| NormalizedIncome | -60.59M | -40.33M | -39.32M | -34.51M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -36.18M | -116.54M | -87.97M | -34.51M |
| TotalExpenses | 70.58M | 43.00M | 39.78M | 36.87M |
| TotalOperatingIncomeAsReported | -43.00M | -88.43M | -36.87M | |
| DilutedAverageShares | 48.54M | 24.62M | 14.29M | 14.82M |
| BasicAverageShares | 48.54M | 24.62M | 14.29M | 14.82M |
| DilutedEPS | -0.66 | -3.74 | -6.16 | -2.33 |
| BasicEPS | -0.66 | -3.74 | -6.16 | -2.33 |
| DilutedNIAvailtoComStockholders | -36.18M | -116.54M | -87.97M | -34.51M |
| NetIncomeCommonStockholders | -36.18M | -116.54M | -87.97M | -34.51M |
| NetIncome | -36.18M | -116.54M | -87.97M | -34.51M |
| NetIncomeIncludingNoncontrollingInterests | -36.18M | -116.54M | -87.97M | -34.51M |
| NetIncomeContinuousOperations | -36.18M | -116.54M | -87.97M | -34.51M |
| TaxProvision | 431.00K | 0.00 | 0.00 | -2.35M |
| PretaxIncome | -35.75M | -116.54M | -87.97M | -36.86M |
| OtherIncomeExpense | 34.82M | -73.54M | -48.19M | 7.00K |
| OtherNonOperatingIncomeExpenses | 3.92M | 2.67M | 462.00K | 7.00K |
| SpecialIncomeCharges | 0.00 | -48.65M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 48.65M | 0.00 | |
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | 30.90M | -76.21M | ||
| NetNonOperatingInterestIncomeExpense | 0.00 | |||
| OperatingIncome | -70.58M | -43.00M | -39.78M | -36.87M |
| OperatingExpense | 70.58M | 43.00M | 39.78M | 36.87M |
| ResearchAndDevelopment | 51.96M | 30.31M | 27.08M | 23.73M |
| SellingGeneralAndAdministration | 18.61M | 12.69M | 12.70M | 13.13M |
| GeneralAndAdministrativeExpense | 18.61M | 12.69M | 12.70M | 13.13M |
| OtherGandA | 18.61M | 12.69M | 12.70M | 13.13M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 59.79M | 24.21M | 13.78M | 14.31M |
| ShareIssued | 59.79M | 24.21M | 13.78M | 14.31M |
| TotalDebt | 954.00K | 383.00K | 746.00K | 769.00K |
| TangibleBookValue | 30.06M | -80.87M | 51.80M | 82.96M |
| InvestedCapital | 62.45M | -48.49M | 84.18M | 164.00M |
| WorkingCapital | 132.15M | 52.23M | 53.04M | 83.94M |
| NetTangibleAssets | 85.75M | -25.18M | 51.80M | 82.96M |
| CapitalLeaseObligations | 954.00K | 383.00K | 746.00K | 769.00K |
| CommonStockEquity | 62.45M | -48.49M | 84.18M | 164.00M |
| PreferredStockEquity | 55.69M | 55.69M | ||
| TotalCapitalization | 118.14M | 7.21M | 84.18M | 164.00M |
| TotalEquityGrossMinorityInterest | 118.14M | 7.21M | 84.18M | 164.00M |
| StockholdersEquity | 118.14M | 7.21M | 84.18M | 164.00M |
| GainsLossesNotAffectingRetainedEarnings | 26.00K | 0.00 | ||
| OtherEquityAdjustments | 26.00K | |||
| RetainedEarnings | -355.59M | -319.40M | -202.87M | -114.90M |
| AdditionalPaidInCapital | 417.95M | 270.89M | 287.03M | 278.88M |
| CapitalStock | 55.75M | 55.72M | 14.00K | 14.00K |
| CommonStock | 60.00K | 24.00K | 14.00K | 14.00K |
| PreferredStock | 55.69M | 55.69M | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 59.27M | 81.86M | 8.61M | 6.55M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 47.69M | 77.96M | 2.13M | 2.15M |
| DerivativeProductLiabilities | 44.87M | 76.21M | 0.00 | |
| NonCurrentDeferredLiabilities | 2.18M | 1.75M | 1.75M | 1.75M |
| NonCurrentDeferredTaxesLiabilities | 2.18M | 1.75M | 1.75M | 1.75M |
| LongTermDebtAndCapitalLeaseObligation | 640.00K | 0.00 | 383.00K | 400.00K |
| LongTermCapitalLeaseObligation | 640.00K | 0.00 | 383.00K | 400.00K |
| CurrentLiabilities | 11.58M | 3.90M | 6.47M | 4.40M |
| CurrentDebtAndCapitalLeaseObligation | 314.00K | 383.00K | 363.00K | 369.00K |
| CurrentCapitalLeaseObligation | 314.00K | 383.00K | 363.00K | 369.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.60M | 2.00M | 1.91M | 1.51M |
| PayablesAndAccruedExpenses | 9.66M | 1.51M | 4.20M | 2.52M |
| CurrentAccruedExpenses | 3.83M | 542.00K | 2.00M | 704.00K |
| Payables | 5.83M | 967.00K | 2.20M | 1.81M |
| AccountsPayable | 5.83M | 967.00K | 2.20M | 1.81M |
| TotalAssets | 177.41M | 89.07M | 92.79M | 170.55M |
| TotalNonCurrentAssets | 33.67M | 32.94M | 33.27M | 82.20M |
| OtherNonCurrentAssets | 363.00K | 186.00K | 150.00K | 400.00K |
| GoodwillAndOtherIntangibleAssets | 32.39M | 32.39M | 32.39M | 81.03M |
| OtherIntangibleAssets | 32.39M | 32.39M | 32.39M | 32.39M |
| Goodwill | 0.00 | 48.65M | ||
| NetPPE | 926.00K | 365.00K | 739.00K | 768.00K |
| GrossPPE | 926.00K | 365.00K | 739.00K | 768.00K |
| OtherProperties | 365.00K | 739.00K | 768.00K | |
| BuildingsAndImprovements | 926.00K | 365.00K | 739.00K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 143.73M | 56.13M | 59.52M | 88.35M |
| OtherCurrentAssets | 729.00K | 90.00K | 28.00K | 34.00K |
| PrepaidAssets | 2.82M | 4.94M | 3.08M | 3.48M |
| Receivables | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 140.18M | 51.10M | 56.41M | 84.83M |
| OtherShortTermInvestments | 119.63M | 46.49M | 0.00 | |
| CashAndCashEquivalents | 20.55M | 4.61M | 56.41M | 84.83M |
| CashEquivalents | 9.30M | 9.30M | ||
| CashFinancial | 47.11M | 75.53M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -47.27M | -39.53M | -28.42M | -28.91M |
| IssuanceOfCapitalStock | 133.31M | 33.02M | 0.00 | 0.00 |
| EndCashPosition | 20.55M | 4.61M | 56.41M | 84.83M |
| BeginningCashPosition | 4.61M | 56.41M | 84.83M | 114.19M |
| ChangesInCash | 15.94M | -51.80M | -28.42M | -29.36M |
| FinancingCashFlow | 133.52M | 33.02M | 0.00 | -449.00K |
| CashFlowFromContinuingFinancingActivities | 133.52M | 33.02M | 0.00 | -449.00K |
| NetOtherFinancingCharges | -450.00K | |||
| ProceedsFromStockOptionExercised | 215.00K | 0.00 | 0.00 | 1.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 133.31M | 33.02M | 0.00 | 0.00 |
| CommonStockIssuance | 133.31M | 33.02M | 0.00 | 0.00 |
| InvestingCashFlow | -70.31M | -45.29M | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | -70.31M | -45.29M | 0.00 | 0.00 |
| NetInvestmentPurchaseAndSale | -70.31M | -45.29M | 0.00 | |
| SaleOfInvestment | 85.82M | 33.00M | 0.00 | |
| PurchaseOfInvestment | -156.13M | -78.29M | 0.00 | |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| OperatingCashFlow | -47.27M | -39.53M | -28.42M | -28.91M |
| CashFlowFromContinuingOperatingActivities | -47.27M | -39.53M | -28.42M | -28.91M |
| ChangeInWorkingCapital | 8.71M | -4.92M | 2.37M | -152.00K |
| ChangeInOtherCurrentLiabilities | -339.00K | -363.00K | -367.00K | -200.00K |
| ChangeInPayablesAndAccruedExpense | 7.75M | -2.60M | 2.08M | 2.14M |
| ChangeInPayable | 7.75M | -2.60M | 2.08M | |
| ChangeInAccountPayable | 7.75M | -2.60M | 2.08M | |
| ChangeInPrepaidAssets | 1.30M | -1.95M | 654.00K | -2.10M |
| OtherNonCashItems | -10.00K | |||
| StockBasedCompensation | 13.12M | 6.54M | 8.15M | 7.90M |
| AssetImpairmentCharge | 0.00 | 48.65M | 0.00 | |
| AmortizationOfSecurities | -2.80M | -1.20M | 0.00 | |
| DeferredTax | 431.00K | 0.00 | 0.00 | -2.35M |
| DeferredIncomeTax | 431.00K | 0.00 | 0.00 | -2.35M |
| DepreciationAmortizationDepletion | 359.00K | 374.00K | 373.00K | 195.00K |
| DepreciationAndAmortization | 359.00K | 374.00K | 373.00K | 195.00K |
| Depreciation | 359.00K | 374.00K | 373.00K | 195.00K |
| OperatingGainsLosses | -30.90M | 76.21M | ||
| GainLossOnInvestmentSecurities | -30.90M | 76.21M | ||
| NetIncomeFromContinuingOperations | -36.18M | -116.54M | -87.97M | -34.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ELDN
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|